14.03.2014

New viruses for cancer therapy meeting clinical needs

A collection of viruses grouped according to common antigenic epitopes that are recognized by the same immune serum. A ubiquitously expressed type-1 transmembrane protein that functions to regulate complement. A chemotherapeutic drug that is dependent on enzymatic activation to achieve full activity. Chemotherapeutic drugs that incorporate into replicating DNA as nucleosides but halt DNA replication, which leads to cell death.
Radioactive isotopes that emit ionizing radiation in the form of high-energy electromagnetic γ rays. Radioactive isotopes that emit ionizing radiation in the form of high-energy, high-speed electrons or protons. Register for the Cancer & Immunotherapy Symposium, April 15-16, immediately prior to the 2016 Annual AACR Meeting in New Orleans, Louisiana (USA).
While traditional small molecule chemotherapy continues to play a critical role in cancer treatment, immunotherapy is rapidly gaining traction. Two abstracts have been selected by the meeting committee for late-breaking podium presentations.
From top to bottom: targeting cell entry (detargeting from natural receptors and retargeting to tumour surface markers) and post-entry targeting (targeting of transcription, replication or microRNAs (miRNAs)). As a requirement of the Paediatric Regulation, all new medicinal products developed for the treatment of HIV-1 infection in adults, must have an agreed paediatric investigation plan (PIP) in place, ensuring the necessary data are obtained to support the medicine's authorisation for use in children, when appropriate.
On 8 June 2015, the European Medicines Agency is organising a workshop on the therapeutic use of bacteriophages, bringing together experts and stakeholders from the academic, industrial and regulatory sectors to discuss different aspects of using bacteriophages to treat bacterial infections.
The workshop brought together experts from national competent authorities and industry to debate how to improve the availability of veterinary vaccines, a topic of high priority for both European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) for many years.


This is an expert meeting on the clinical investigation of medicines for the treatment of paediatric hepatitis C.
MiestTanner Miest is a student in the Medical Scientist Training Program at the Mayo Clinic College of Medicine, Rochester, Minnesota, USA. An immuno-stimulatory cytokine that functions as a growth factor for granulocytes and monocytes. An immunoglobulin-like transmembrane cell adhesion protein that is used by some coxsackievirus and adenovirus species as a receptor. It functions as a receptor for vaccine strains of measles virus and some adenovirus species. They are capable of initiating new tumour growth and may drive tumour recurrence after therapy. The aim is to proactively discuss current issues and open questions and reflect on potential ways forward for this therapy with various stakeholders. The meeting concluded that the reasons why more veterinary vaccines are not available in the European Union (EU) are complex and relate to the approach to management of risk and uncertainty, technical requirements and administrative procedures. The aim of the expert meeting is to take up-to-date scientific developments in understanding and treating hepatitis C into consideration when discussing Paediatric Development Plans and to discuss how the therapeutic needs for paediatric hepatitis C can be better addressed. Tumours have decreased expression of certain miRNAs, which renders them unable to restrict vector replication. He graduated with an honours degree in biology from the Gustavus Adolphus College, St Peter, Minnesota, USA, and recently completed the Ph.D.
The purpose of this expert meeting is to advise the EMA and the PDCO on the best development pathways for fixed-dose combinations for the treatment of children and adolescents living with HIV.
The two glycoproteins of this monotypic virus are substituted by the glycoproteins of an animal virus of the same genus.


He completed his undergraduate training at the University of Geneva, Switzerland, and received his Ph.D.
In responding patients, the candidate nearly doubled the median overall survival, which is impressive.As one of the few unicorns in European Biotech, Immunocore develops ImmTACs.
He was a postdoctoral fellow at the University of Zurich, Switzerland, and a visiting scientist at Yale University, Connecticut, USA.
He received the Venia Legendi from the University of Zurich in 1993 and has been Professor of Biochemistry and Molecular Biology at the Mayo Clinic College of Medicine since 2000.
In mice with tumors resistant to the action of anti-PD-1 (the most common checkpoint inhibitor), treatment with 4SC-202 led to reduction in tumor size.With its huge antibody libraries, MorphoSys is currently in clinical trials with more than 20 candidates. At ASCO, MorphoSys presented data on therapies for different types of blood cancer.The anti-CD38 antibody to treat multiple myeloma, MOR202, has shown no adverse reactions when infused. This Biotech is targeting the most frequently mutated gene in human cancer (p53) with a small molecule (APR-246).
Required fields are marked * Labiotech.eu is the leading digital media covering the European Biotech industry.
It is used by over 40,000 people monthly to keep a watch on the business and innovations of biotechnologies.
Join them for free and enjoy reading our stories!« Let?s change how people get informed about Biotechs in Europe.



Online directory for environmental products
Treatment resistant headaches


Comments to «New viruses for cancer therapy meeting clinical needs»

  1. Joker writes:
    (BL-18) the following day, alternating remedies for a total.
  2. Sheyla writes:
    Sufferers noticed by international delegations had been preselected for prime the world, together.